CA-AIRSPACE-TECH
10.12.2020 14:02:12 CET | Business Wire | Press release
Airspace Technologies, Inc. (Airspace), the company revolutionizing air cargo and time-critical logistics, has opened its first European office, with the launch of Airspace B.V. From the headquarters, located at Schiphol-Rijk, the Netherlands, which opened in June this year, Airspace will be expanding its team across the Netherlands, France, Germany, and the U.K., in line with its rapid growth plans to fulfill customer demand.
Airspace’s technology is transforming and modernizing the logistics industry. Their proprietary software uses machine learning to identify the fastest and lowest risk path out of millions of possibilities. The technology proactively ensures that any potential delays are avoided and guarantees the customer real-time, end-to-end visibility. While officials anticipate significant problems at the borders due to Brexit, Airspace’s technology will greatly reduce the impact of the logistics issues for the customer and allow vital products and services to still be delivered on time.
The new European operation will be managed by Marcel Andriessen, who has successfully led logistics companies specializing in worldwide time-critical services over the last 20 years. Andriessen was the Managing Director at time:matters for 10 years and was responsible for the success of their European business and the expansion into the U.S. Andriessen will lead the Airspace BV organization as Managing Director.
“I am looking forward to getting back into time-critical logistics and to bring Airspace’s leading-edge technology to the European market. Customers here have not experienced the speed and transparency that Airspace offers, and I welcome the opportunity to show them how much better time-critical logistics can be,” said Andriessen.
The company’s expansion is in response to the demand from global customers who want to further leverage the Airspace technology for their European operations. Industry-leading customers including Quest Diagnostics, Varian Medical, and Allegiant Air Corporation, already rely on Airspace’s proprietary logistics technology and robust delivery network to deliver their mission-critical shipments as fast as possible throughout North America and Europe. They rely on the technology platform Airspace has developed to provide real-time, door-to-door transparency throughout the entire shipment process. This is most important for life-saving industries, such as the medical profession, which depend on rapid deliveries.
“The time-critical market is full of difficult problems. Customers too often have a poor experience because the industry is trying to solve these problems using antiquated practices. Shippers across Europe need a modern platform that can provide the level of transparency and error prevention that these critical shipments deserve,” said Nick Bulcao, Co-Founder & CEO of Airspace Technologies, Inc.
About Airspace Technologies, Inc.
Based in Carlsbad, Calif., Airspace Technologies, Inc. was founded in 2015 and has grown to be the most trusted leader in time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints within a shipment, Airspace surfaces more information than any other provider, increasing the velocity and transparency of the supply chain.
To learn more about Airspace, please visit www.airspacetechnologies.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005537/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom